PMID- 24626097
OWN - NLM
STAT- MEDLINE
DCOM- 20150415
LR  - 20211021
IS  - 1552-695X (Electronic)
IS  - 1534-7354 (Print)
IS  - 1534-7354 (Linking)
VI  - 13
IP  - 5
DP  - 2014 Sep
TI  - Dietary quercetin reduces chemotherapy-induced fatigue in mice.
PG  - 417-24
LID - 10.1177/1534735414523315 [doi]
AB  - PURPOSE: While fatigue is the most commonly reported symptom of chemotherapy, 
      there are currently no effective treatments for chemotherapy-induced fatigue 
      (CIF). We used a mouse model to examine the benefits of quercetin on CIF as 
      measured by voluntary wheel running activity and sought to determine whether 
      quercetin may be associated with a decrease in inflammation and/or anemia. 
      METHODS: Mice were assigned to 1 of 4 groups: placebo-vehicle (Plac-PBS), 
      placebo-5-fluorouracil (Plac-5FU), quercetin-vehicle (Quer-PBS), or 
      quercetin-5-fluorouracil (Quer-5FU). All mice were given a daily injection of 
      either 60 mg/kg of 5-FU or phosphate buffered saline (PBS) for 5 days. Quercetin 
      (0.02%) treatment was administered in the food 3 days prior to 5-FU 
      administration and for the duration of the experiment (ie, days -2 to 14). A 
      second group of mice was sacrificed at 5 and 14 days post initial injection for 
      assessment of monocyte chemoattractant protein-1 (MCP-1) and anemia. RESULTS: 
      Voluntary wheel running was reduced in both the Plac-5FU and Quer-5FU groups 
      following 5-FU injection (P < .05). However, the Quer-5FU group recovered to 
      baseline levels by approximately day 7, whereas the Plac-5FU group remained 
      suppressed. MCP-1 was significantly elevated at 14 days in Plac-5FU (P < .001), 
      but no changes were seen with Quer-5FU. Treatment with 5-FU resulted in anemia at 
      both 5 days and 14 days; however, quercetin blocked this effect at 14 days (P < 
      .001). CONCLUSION: These results demonstrate the beneficial effect of quercetin 
      on improving recovery of voluntary physical activity following 5-FU treatment, 
      which may be linked to a decrease in inflammation and anemia.
CI  - (c) The Author(s) 2014.
FAU - Mahoney, Sara E
AU  - Mahoney SE
AD  - Department of Exercise Science, Lansing School of Nursing, Bellarmine University, 
      Louisville, KY, USA smahoney@bellarmine.edu.
FAU - Davis, J Mark
AU  - Davis JM
AD  - Department of Exercise Science, Arnold School of Public Health, University of 
      South Carolina, Columbia, SC, USA.
FAU - Murphy, E Angela
AU  - Murphy EA
AD  - Department of Pathology, Microbiology and Immunology, School of Medicine, 
      University of South Carolina, Columbia, SC, USA.
FAU - McClellan, Jamie L
AU  - McClellan JL
AD  - Department of Exercise Science, Arnold School of Public Health, University of 
      South Carolina, Columbia, SC, USA.
FAU - Pena, Marjory M
AU  - Pena MM
AD  - Department of Biological Science, University of South Carolina, Columbia, SC, 
      USA.
LA  - eng
GR  - P20 RR017698/RR/NCRR NIH HHS/United States
GR  - P30 GM103336/GM/NIGMS NIH HHS/United States
GR  - R01 CA154731/CA/NCI NIH HHS/United States
PT  - Journal Article
DEP - 20140313
PL  - United States
TA  - Integr Cancer Ther
JT  - Integrative cancer therapies
JID - 101128834
RN  - 0 (Antimetabolites, Antineoplastic)
RN  - 0 (Chemokine CCL2)
RN  - 9IKM0I5T1E (Quercetin)
RN  - U3P01618RT (Fluorouracil)
SB  - IM
MH  - Anemia/chemically induced/prevention & control
MH  - Animals
MH  - Antimetabolites, Antineoplastic/adverse effects
MH  - Chemokine CCL2/metabolism
MH  - *Dietary Supplements
MH  - Disease Models, Animal
MH  - Fatigue/chemically induced/*prevention & control
MH  - Fluorouracil/*adverse effects
MH  - Inflammation/chemically induced/prevention & control
MH  - Mice
MH  - Mice, Inbred C57BL
MH  - Motor Activity/physiology
MH  - Quercetin/administration & dosage/*pharmacology
MH  - Running/physiology
MH  - Time Factors
PMC - PMC4136550
MID - NIHMS613596
OTO - NOTNLM
OT  - anemia
OT  - chemotherapy
OT  - fatigue
OT  - inflammation
OT  - quercetin
COIS- Declaration of Conflicting Interests The author(s) declared no potential 
      conflicts of interest with respect to the research, authorship, and/or 
      publication of this article.
EDAT- 2014/03/15 06:00
MHDA- 2015/04/16 06:00
PMCR- 2015/09/01
CRDT- 2014/03/15 06:00
PHST- 2014/03/15 06:00 [entrez]
PHST- 2014/03/15 06:00 [pubmed]
PHST- 2015/04/16 06:00 [medline]
PHST- 2015/09/01 00:00 [pmc-release]
AID - 1534735414523315 [pii]
AID - 10.1177/1534735414523315 [doi]
PST - ppublish
SO  - Integr Cancer Ther. 2014 Sep;13(5):417-24. doi: 10.1177/1534735414523315. Epub 
      2014 Mar 13.